JP2017518982A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518982A5
JP2017518982A5 JP2016567865A JP2016567865A JP2017518982A5 JP 2017518982 A5 JP2017518982 A5 JP 2017518982A5 JP 2016567865 A JP2016567865 A JP 2016567865A JP 2016567865 A JP2016567865 A JP 2016567865A JP 2017518982 A5 JP2017518982 A5 JP 2017518982A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
epiamb
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518982A (ja
JP6543272B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030965 external-priority patent/WO2015175875A1/en
Publication of JP2017518982A publication Critical patent/JP2017518982A/ja
Publication of JP2017518982A5 publication Critical patent/JP2017518982A5/ja
Application granted granted Critical
Publication of JP6543272B2 publication Critical patent/JP6543272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567865A 2014-05-16 2015-05-15 低減された毒性を有するアンホテリシンb誘導体 Active JP6543272B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461994450P 2014-05-16 2014-05-16
US61/994,450 2014-05-16
US201462045907P 2014-09-04 2014-09-04
US62/045,907 2014-09-04
PCT/US2015/030965 WO2015175875A1 (en) 2014-05-16 2015-05-15 Amphotericin b derivative with reduced toxicity

Publications (3)

Publication Number Publication Date
JP2017518982A JP2017518982A (ja) 2017-07-13
JP2017518982A5 true JP2017518982A5 (enExample) 2018-06-28
JP6543272B2 JP6543272B2 (ja) 2019-07-10

Family

ID=54480735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567865A Active JP6543272B2 (ja) 2014-05-16 2015-05-15 低減された毒性を有するアンホテリシンb誘導体

Country Status (7)

Country Link
US (1) US9738677B2 (enExample)
EP (1) EP3142672B1 (enExample)
JP (1) JP6543272B2 (enExample)
CA (1) CA2981288C (enExample)
DK (1) DK3142672T3 (enExample)
ES (1) ES2749927T3 (enExample)
WO (1) WO2015175875A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087206B2 (en) * 2014-10-17 2018-10-02 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin B
EP3283171B1 (en) 2015-04-15 2021-05-26 Sfunga Therapeutics, Inc. Derivatives of amphotericin b
EP3846823A4 (en) * 2018-09-07 2022-04-20 The Board of Trustees of the University of Illinois AMPHOTERICIN B DERIVATIVES HYBRIDS WITH REDUCED TOXICITY
CA3149819A1 (en) * 2019-08-08 2021-02-11 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity
AU2020329149A1 (en) * 2019-08-09 2022-03-03 The Board Of Trustees Of The University Of Illinois Combination treatment of systemic fungal infections
AU2021325676A1 (en) * 2020-08-10 2023-03-30 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin B
CA3261962A1 (en) * 2022-07-08 2024-01-11 The Board Of Trustees Of The University Of Illinois TRANSFER OF C2 EPIMERIZED SUGARS TO AGLYCONIC AMPHOTEROCIBN B

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110473A1 (en) * 2003-05-27 2004-12-23 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
EP1773301A2 (en) * 2004-06-21 2007-04-18 Nektar Therapeutics Compositions comprising amphotericinb methods and systems
WO2014059436A1 (en) * 2012-10-12 2014-04-17 The Board Of Trustees Of The University Of Illinois Electronic tuning of site selectivity
US10087206B2 (en) * 2014-10-17 2018-10-02 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin B

Similar Documents

Publication Publication Date Title
JP2017518982A5 (enExample)
JP2014507446A5 (enExample)
JP2017186358A5 (enExample)
JP2017509667A5 (enExample)
JP2017537066A5 (enExample)
EP4331677A3 (en) Methods of treating feline coronavirus infections
JP2019516735A5 (enExample)
JP2016518337A5 (enExample)
JP2018521020A5 (enExample)
JP2017105793A5 (enExample)
JP2013014622A5 (enExample)
JP2021191784A5 (enExample)
JP2013032389A5 (enExample)
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
EP4616908A3 (en) Oxysterols and methods of use thereof
JP2018531941A5 (enExample)
JP2012092123A5 (enExample)
JP2014167010A5 (enExample)
EP3731847A4 (en) PULSED ADMINISTRATION OF INHALED NITROGEN OXIDE FOR THE TREATMENT OF PULMONIC HYPERTENSION
JP2013519675A5 (enExample)
ME02910B (me) Spojevi tetrahidropirolotiazina
JP2015110588A5 (enExample)
JP2020097577A5 (enExample)
JP2015506363A5 (enExample)
EP3430400A4 (en) DOSAGE PLANS FOR THE TREATMENT OF FUNGI INFECTIONS